Non-tuberculous mycobacterial pulmonary disease
NTM lung · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
NTM pulmonary disease (commonly Mycobacterium avium complex or M. abscessus) causes chronic cough, bronchiectasis and nodular/cavitary disease, especially in older women and those with structural lung disease. Diagnosis requires clinical, radiological and microbiological criteria; treatment is prolonged multidrug therapy.
Red flags
- Haemoptysis or massive haemoptysis
- Progressive cavitation and weight loss
- Macrolide resistance on susceptibility testing
- Rapid clinical deterioration suggesting disseminated/immunodeficient disease
Assessment
Differential diagnosis
- Tuberculosis
- Bronchiectasis from other cause
- Aspergillosis
- Lung cancer
- Chronic bacterial bronchial infection
Investigations
- HRCT chest (nodular bronchiectasis, tree-in-bud, cavitation)
- At least two separate sputum cultures positive for the same NTM species (or one positive BAL/biopsy)
- Species identification and drug-susceptibility testing (macrolide, amikacin)
- Exclude/treat TB and other pathogens
- Spirometry and weight/nutrition assessment
- Screen for predisposing conditions (CF, alpha-1 antitrypsin, immunodeficiency, GORD)
Management
- Confirm NTM disease using ATS/ERS/IDSA clinical, radiological and microbiological criteria (not colonisation)
- Identify species and obtain susceptibility, especially macrolide and amikacin
- Assess disease severity: nodular-bronchiectatic vs fibrocavitary and symptom burden
- Decide whether to treat or observe — not all disease needs immediate therapy
- For MAC, start guideline multidrug therapy with a macrolide-ethambutol-rifamycin backbone
- Add or switch to IV/inhaled amikacin for cavitary, severe or refractory disease
- Treat M. abscessus with an initial intensive IV phase then a prolonged continuation regimen
- Continue therapy until culture-negative for at least 12 months
- Optimise airway clearance, nutrition and comorbidities; treat concurrent bronchiectasis
- Monitor for drug toxicity (vision, hearing, renal, hepatic) and consider surgery for localised refractory disease
Drugs & doses
Azithromycin 250-500 mg PO once daily (or 500 mg three times weekly) — macrolide backbone
Ethambutol 15 mg/kg PO once daily
Rifampicin 600 mg PO once daily (rifabutin alternative)
Amikacin liposomal inhalation 590 mg nebulised once daily for refractory MAC; or IV amikacin 15 mg/kg for severe disease
M. abscessus: IV amikacin + imipenem or cefoxitin + oral macrolide (if susceptible) induction
Disposition
Specialist respiratory / mycobacterial clinic; long-term monitored multidrug therapy; thoracic surgery for localised refractory disease.
Complications & pitfalls
- Chronic respiratory failure and progressive bronchiectasis
- Drug toxicity (ocular, ototoxicity, hepatotoxicity, renal)
- Macrolide-resistant treatment failure
- Massive haemoptysis / aspergilloma in cavities
Exam pearls
- Never use a macrolide as monotherapy — it breeds resistance; always combine
- Isolating NTM once often reflects colonisation; diagnosis needs repeated positives plus disease
- M. abscessus is notoriously hard to cure and often requires surgery
- Classic 'Lady Windermere' phenotype: slim older woman with lingula/middle-lobe nodular bronchiectasis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.